CD16A and CD19 — Drug Target

All drugs that target CD16A and CD19 — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

Bispecific antibody

Phase 2 pipeline (1)

• Bispecific antibody · Sung-Soo Park · Bispecific antibody · Oncology
  Binds to CD16A and CD19 to activate antibody-dependent cellular cytotoxicity and antibody-dependent cellular phagocytosis